Isoquercetin for ovarian cancer patients
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests if a plant-based supplement called isoquercetin can help people with ovarian cancer when given alongside their first chemotherapy. It aims to see if it improves treatment results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian cancer (a type called epithelial, serous, or clear cell).
- You are about to start or are in your first or second cycle of chemotherapy.
- You are at least 18 years old.
- Your doctor expects you to live more than 6 months.
- You are generally active and able to do daily activities (performance status score of 0 or 1).
- You have no history of blood clots, bleeding problems, or use of blood thinners in the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This study tests a new pill called INCB123667 for people with a type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow their growth.
This early-phase trial tests a lab-made immune cell treatment designed to recognize ovarian cancer and attack it. It may help people with high-risk ovarian cancer who still need effective options.
This trial tests a new drug called azenosertib against standard chemotherapy for ovarian, fallopian tube, or peritoneal cancer that has come back after platinum-based treatment. The drug targets a specific protein (cyclin E1) found in some tumors and may help stop cancer cells from dividing.
This study looks at ovarian cancer patients who are planned to receive platinum-based chemotherapy and who may have resistance issues. It may help doctors learn better ways to treat ovarian cancer when platinum drugs don’t work well.
This trial tests a combination of three drugs—pembrolizumab (Keytruda, an immunotherapy), bevacizumab (Avastin, a blood-vessel blocker), and oral cyclophosphamide (a chemotherapy pill)—for women with high-grade ovarian cancer who have only tiny bits of disease left after finishing their initial treatment.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.